TABLE 2.
Median survival outcomes for included patients
| Outcome (months) | Median RFS (95% CI) | Median SAR (95% CI) | Median OS (95% CI) | Median DSS (95% CI) |
|---|---|---|---|---|
| All patients [n = 877] | 15.5 (14.1–16.8) | 7.3a (6.6–7.95) | 24.8 (23.2–26.4) | 27.5 (25.0–30.0) |
| No recurrence [n = 188] | NAb | NA | 83.9 (59.3–108.6) | NAb |
| Lung-only [n = 93] | 18.4 (14.8–22.1) | 15.4 (10.9–19.9) | 39.6 (29.3–50.0) | 44.9 (36.5–53.4) |
| Local-only [n = 158] | 14.2 (12.6–15.9) | 9.7 (7.5–12.0) | 26.2 (22.8–29.5) | 28.5 (25.2–31.9) |
| Other [n = 18] | 15.5 (14.9–16.1) | 8.0 (1.8–14.3) | 29.4 (23.5–35.3) | 29.4 (12.5–46.3) |
| Multiple-site [n = 227] | 11.1 (9.8–12.4) | 4.7 (3.8–5.1) | 17.7 (16.2–19.3) | 18.1 (16.3–20.0) |
| Liver-only [n = 166] | 7.3 (5.9–8.7) | 7.2 (6.0–8.5) | 15.4 (13.1–17.6) | 15.5 (13.3–17.7) |
RFS recurrence-free survival, SAR survival after recurrence, OS overall survival, DSS disease-specific survival, CI confidence interval, NA not applicable
a
For all patients with recurrence [n = 662]
b
Not computable separately as all cases were censored